<code id='A7A0166E8E'></code><style id='A7A0166E8E'></style>
    • <acronym id='A7A0166E8E'></acronym>
      <center id='A7A0166E8E'><center id='A7A0166E8E'><tfoot id='A7A0166E8E'></tfoot></center><abbr id='A7A0166E8E'><dir id='A7A0166E8E'><tfoot id='A7A0166E8E'></tfoot><noframes id='A7A0166E8E'>

    • <optgroup id='A7A0166E8E'><strike id='A7A0166E8E'><sup id='A7A0166E8E'></sup></strike><code id='A7A0166E8E'></code></optgroup>
        1. <b id='A7A0166E8E'><label id='A7A0166E8E'><select id='A7A0166E8E'><dt id='A7A0166E8E'><span id='A7A0166E8E'></span></dt></select></label></b><u id='A7A0166E8E'></u>
          <i id='A7A0166E8E'><strike id='A7A0166E8E'><tt id='A7A0166E8E'><pre id='A7A0166E8E'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:Wikipedia    - browse:63
          3d heart myocarditis
          Adobe

          A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

          The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

          advertisement

          In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus